SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

UPDATE: Piper Jaffray On Nektar Also Notes 'We look forward to the melanoma/PIVOT-02 cohort update at SITC this weekend and are encouraged to see more of the pipeline advance into clinical development (255/IL-15 and 358/T-reg)'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · -